One Health drivers of antibacterial resistance: quantifying the relative impacts of human, animal and environmental use and transmission

4

5 Ross D. Booton¹, Aronrag Meeyai^{2,3}, Nour Alhusein⁴, Henry Buller⁵, Edward Feil⁶,

6 Helen Lambert⁴, Skorn Mongkolsuk⁷, Emma Pitchforth⁸ Kristen K. Reyher¹,

7 Walasinee Sakcamduang⁹, Jutamaad Satayavivad¹⁰, Andrew C. Singer¹¹, Luechai

8 Sringernyuang¹², Visanu Thamlikitkul¹³, Lucy Vass¹, **OH-DART study group**,

9 Matthew B. Avison¹⁴, Katherine M.E. Turner^{1*}

10

11 ¹Bristol Veterinary School, University of Bristol, Bristol, UK

12 ²Department of Epidemiology, Mahidol University, Bangkok, Thailand

13 ³Department of Global Health and Development, London School of Hygiene and Tropical Medicine, UK

14 ⁴Bristol Medical School, University of Bristol, Bristol, UK

15 ⁵College of Life and Environmental Sciences, University of Exeter, Exeter, UK

16 ⁶Department of Biology & Biochemistry, University of Bath, Bath, UK

17 ⁷Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand

18 ⁸College of Medicine and Health, University of Exeter, Exeter, UK

19 ⁹Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand

20 10 Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand

21 ¹¹UK Centre for Ecology & Hydrology, Wallingford, UK

22 ¹²Faculty of Social Sciences and Humanities, Mahidol University, Bangkok, Thailand

23 ¹³Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

24 ¹⁴School of Cellular & Molecular Medicine, University of Bristol, Bristol, UK

25 *Corresponding author: <u>Katy.Turner@bristol.ac.uk</u>

26

27 **OH-DART** study group:

28 Matthew B. Avison (University of Bristol, UK), Nour Alhusein (University of Bristol, UK), Ross D. Booton (University of Bristol, UK), 29 Henry Buller (University of Exeter, UK), Boonrat Chantong (Mahidol University, Thailand), Nisanart Charoenlap (Chulabhorn 30 Research Institute, Thailand), Natacha Couto (University of Bath, UK), Punyawee Dulyayangkul University of Bristol, UK), Edward 31 Feil (University of Bath, UK), Marjorie J. Gibbon (University of Bath, UK), Virginia C. Gould (University of Bristol, UK), Helen 32 Lambert (University of Bristol, UK), Aronrag Meeyai (Mahidol University, Thailand, London School of Hygiene and Tropical 33 Medicine, UK), Skorn Mongkolsuk (Chulabhorn Research Institute, Thailand), Varapon Montrivade (Mahidol University, Thailand), 34 Emma Pitchforth (University of Exeter, UK), Kornrawan Phoonsawad (Mahidol University, Thailand), Nuchanart Rangkadilok 35 (Chulabhorn Research Institute, Thailand), Parntep Ratanakorn (Chulabhorn Royal Academy, Thailand), Kristen K. Reyher 36 (University of Bristol, UK), Walasinee Sakcamduang (Mahidol University, Thailand), Jutamaad Satayavivad (Chulabhorn 37 Research Institute, Thailand), Andrew C. Singer (Centre for Ecology & Hydrology, UK), Kwanrawee Sirikanchana (Chulabhorn

38 Research Institute, Thailand), Luechai Sringernyuang (Mahidol University, Thailand), Tawit Suriyo (Chulabhorn Research

39 Institute, Thailand), Sarin Suwanpakdee (Mahidol University, Thailand), Visanu Thamlikitkul (Mahidol University, Thailand),

40 Katherine M.E. Turner (University of Bristol, UK), Lucy Vass (University of Bristol, UK), Kantima Wichuwaranan (Mahidol

41 University, Thailand), Anuwat Wiratsudakul (Mahidol University, Thailand).

42 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 **Abstract**

44 Introduction Antimicrobial resistance (AMR), particularly antibacterial resistance 45 (ABR) is a major global health security threat projected to cause over ten million human deaths annually by 2050. There is a disproportionate burden of ABR within 46 47 lower- and middle-income countries (LMICs), but it is not well understood how 'One 48 Health' drivers, where human health is co-dependent on the health of animals and 49 environmental factors, might also impact the burden of ABR in different countries. 50 Thailand's "National Strategic Plan on Antimicrobial Resistance in Thailand" (NSP-51 AMR) aims to reduce AMR morbidity by 50% through a reduction of 20% in human antibacterial use and a 30% reduction in animal use starting in 2017. There is a need 52 53 to understand the implications of such a plan within a One Health perspective that 54 mechanistically links humans, animals and the environment.

55

56 Methods A mathematical model of antibacterial use, gut colonisation with extended-57 spectrum beta-lactamase (ESBL)-producing bacteria and faecal/oral transmission 58 between populations of humans, animals and the environment was calibrated using 59 estimates of the prevalence of ESBL-producing bacteria in Thailand, taken from 60 published studies. This model was used to project the reduction in human ABR (% reduction in colonisation with resistant bacteria) over 20 years (2020-2040) for each 61 62 potential One Health driver, including each individual transmission rate between humans, animals and the environment, exploring the sensitivity of each parameter 63 64 calibrated to Thai-specific data. The model of antibacterial use and ABR transmission 65 was used to estimate the long-term impact of the NSP-AMR intervention and quantify 66 the relative impacts of each driver on human ABR.

67

Results Our model predicts that human use of antibacterials is the most important 68 factor in reducing the colonisation of humans with resistant bacteria (accounting for 69 maximum 72.3 - 99.8% reduction in colonisation over 20 years). The current NSP-70 71 AMR is projected to reduce the human burden of ABR by 7.0 - 21.0%. If a more ambitious target of 30% reduction in antibacterial use in humans were set, a greater 72 73 (9.9 – 27.1%) reduction in colonisation among humans is projected. We project that 74 completely limiting antibacterial use within animals could have a lower impact (maximum 0.8 – 19.0% reductions in the colonisation of humans with resistant bacteria 75

over 20 years), similar to completely stopping animal-to-human transmission (0.5 - 17.2%). Entirely removing environmental contamination of antibacterials was projected to reduce the percentage colonisation of humans with resistant bacteria by 0.1 - 6.2%, which was similar to stopping environment-human transmission (0.1 - 6.1%).

81

Discussion Our current understanding of the interconnectedness of ABR in a One 82 Health setting is limited and precludes the ability to generate projected outcomes from 83 84 existing ABR action plans (due to a lack of fit-for-purpose data). Using a theoretical 85 approach, we explored this using the Thai AMR action plan, using the best available 86 parameters to model the estimated impact of reducing antibacterial use and 87 transmission of resistance between populations. Under the assumptions of our model, 88 human use of antibacterials was identified as the main driver of human ABR, with 89 slightly more ambitious reductions in usage (30% versus 20%) predicted to achieve 90 higher impacts within the NSP-AMR programme. Considerable long-term impact may 91 be also achieved through increasing the rate of loss of resistance and limiting One 92 Health transmission events, particularly human-to-human transmission. Our model 93 provides a simple framework to explain the mechanisms underpinning ABR, but 94 further empirical evidence is needed to fully explain the drivers of ABR in LMIC 95 settings. Future interventions targeting the simultaneous reduction of transmission and 96 antibacterial usage would help to control ABR more effectively in Thailand.

97

98 Keywords antibacterial resistance; mathematical model; One Health; transmission;

99 antibacterial usage; Thailand; intervention

101 Introduction

Antimicrobials have played an important role in the treatment and prevention of 102 infectious diseases, have enabled food production to intensify and have greatly 103 104 improved the lives of many millions of people. However, the emergence and spread 105 of antimicrobial resistance (AMR) threatens to undermine this progress, with drugresistant pathogens projected to cause ten million annual deaths by 2050 [1]. Hence 106 107 AMR is regarded as a major global health security issue [2], with many member states of the World Health Organization adopting national action plans (with different stages 108 109 of financing and implementation) in order to tackle the growing threat of AMR [3]. 110

111 AMR, particularly Antibacterial Resistance (ABR), occurs at the interface of a 112 multifaceted One Health system; human health does not only depend on the human population's health-related behaviour, but also on industrial, farming and veterinary 113 114 practices as well as environmental conditions [4]. In the context of ABR, these diverse 115 drivers can be separated into two components: "selection", predominantly by 116 antibacterial use (ABU) and "transmission" of resistant organisms between each 117 connected compartment on a human-animal-environment axis. In terms of selection, 118 the majority of global ABU is within animals raised for food (73%, [5,6]) and it is 119 generally accepted that ABU in animals drives ABR [7], although the magnitudes of these effects are poorly characterised and are likely to be antibacterial, resistance 120 mechanism and organism specific. However, ABU within human populations (of which 121 up to 50% is unnecessary [8]) is also a fundamental driver of ABR [9]. In terms of 122 123 transmission, sharing of resistant bacteria between humans, animals and the 124 environment can occur via human-human contact (open community, contact with 125 patients, household transmission, contact in workplaces, travellers), human-animal contact (occupational contact with farm animals, food consumption or preparation, 126 127 contact with companion animals), animal-animal contact (relating to farming practices, 128 or movement of wild or domesticated animals), and human-environment or animal-129 environment interfaces (sewage and manure, habitat, drinking water, bathing, leisure 130 activities, food sources and soil) [10]. Crucially, we do not know the full extent to which 131 the listed factors of selection and transmission lead to the currently observed growing 132 prevalence of ABR and increasing incidence of drug-resistant infections.

Selection and transmission of ABR are not entirely independent. ABU drives selection 134 of pre-existing resistant bacteria through population-level mechanisms [11], while 135 136 simultaneously selecting for successful transmission of resistance into the bacterial population (either via the transmission of mobile genetic elements between 137 138 microorganisms or through direct transmission of the microorganisms themselves) [7]. 139 Therefore, while ABU in humans and animals, contamination of the environment from 140 those sources or ABU within non-animal agriculture are known to generally increase 141 the prevalence of ABR, the relationship between ABU and resistance is highly complex. 142 and dependent on pre-existing bacterial population structures [7]. To account for this, 143 previous studies have suggested that no single 'silver bullet' solution exists. Rather, 144 that preventing and reducing the burden of ABR within a One Health system should 145 take a multifactorial, coordinated approach focussing on the specifics of ABU, and the types and prevalence of ABR in each system, while considering the potential 146 147 interactions within and between compartments [7]. It should also take a multi-sector, 148 transdisciplinary, collaborative approach. One Health is a relatively recent global 149 policy framing of ABR [12] and to date, while animal health has been increasingly 150 included in national policies and action plans, the environment has been given less 151 emphasis [13,14]. One Health approaches are promoted widely in the field, yet the 152 relative contributions of different drivers or the impacts of different interventions are not known, and remain unquantified [10]. Quantification could aid the prioritisation of 153 154 interventions and refine policy approaches in the inherently complex field of ABR.

155

While ABR is a global issue [15], there is a disproportionate burden of infectious 156 157 diseases in lower- and middle-income countries (LMICs) [16]. While these countries 158 experience higher rates of infection (up to three times greater than high income 159 countries [17]), emerging evidence suggests the burden of ABR is greater in LMICs 160 [18] while simultaneously there is limited access to essential antibacterials [8]. 161 Perhaps counterintuitively, research focussed on modelling ABR within lower- and 162 middle-income Southeast Asian countries is vastly underrepresented when compared to European or African studies (eight published models in South-East Asia, 35 in Africa 163 164 and 42 in Europe [19]), especially when considering that the prevalence of extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli (i.e. a key resistance 165 166 mechanism and pathogen relevant to human and animal health and a sentinel for One

Health ABR) in Southeast Asia is high (22% in Southeast Asia compared to 4% inEurope [18]).

169

170 Here we focus on the specific national setting of Thailand, an upper-middle income 171 country in Southeast Asia with a high burden of ABR relative to other countries [20] 172 which affects both human health (88 000 infections, 38 000 deaths attributed to ABR 173 per year in 2010) and the economy (direct costs of \$70 - 170 million to treat ABR, indirect costs at least \$1100 million for morbidity in 2010) [21]. The prevalence of 174 175 faecal colonisation with ESBL-producing E. coli among healthy humans in selected 176 communities in Thailand has grown from 0% in 2004 [22] to 69% in 2010 [23] and 74% 177 in 2012 [24]. In response to the threat posed by rising ABR, the Thai cabinet 178 implemented their first five-year policy in 2016, the "National Strategic Plan on 179 Antimicrobial Resistance in Thailand" (NSP-AMR) running until 2021 [25]. The NSP-180 AMR reflects the strategic objectives of the WHO Global Action Plan [3] and aims to reduce AMR morbidity in Thailand by 50% through 20% reductions in AMU in humans, 181 182 30% reductions in AMU in animals and 20% increases in public knowledge on AMR 183 (including awareness of AMU) by 2021 [25].

184

We aim to quantify the relative contributions to the human ABR burden (% colonisation 185 with resistant bacteria) of human, animal and environmental factors (including ABU 186 187 and transmission of ABR bacteria) within a One Health system in Thailand. We 188 propose a simple mathematical framework for the spread of ABR between these 189 compartments from which we will explore and assess national interventions aimed at 190 reducing ABR. Our objective is to assess and compare a wide variety of One Health 191 drivers and provide insights into the multifaceted problem of ABR. This simple model 192 is intended to stimulate further discussion on how best to reduce the burden of ABR 193 in human populations and to provide the much needed first step in providing a 194 workable One Health modelling framework.

195

196 Methods

We built a compartmental model of ordinary differential equations (ODEs) to describe the relationship between resistant bacteria in three compartments: humans, animals and the environment. We considered the fraction of all humans colonised with resistant bacteria (H), the fraction of animals with resistant bacteria (A) and the fraction of environmental samples with resistant bacteria (E) based on the framework of a previously published model of animal-human transmission [26]. Here, we assume that the bacteria are ESBL-producing *E. coli*, and human/animal colonisation is assumed to be of the gut and via the faecal-oral route. Given our use of a sentinel pre-evolved resistance mechanism, *de novo* selection of resistance within a compartment is not considered significant.

207

We assumed that resistance develops from two sources; antibacterial use (*Box 1A*, which selects resistant bacteria already present in the host) and transmission from other compartments (*Box 1B*, which is also dependent on antibacterial use in those compartments).

212

First, resistance develops in humans from exposure to antibacterials, proportional to their usage in medicine $\Lambda_{\rm H}$, the rate at which humans are colonised with resistant bacteria, γ , and the fraction of humans not already colonised (1 - H). In a similar fashion, resistance develops in animals proportional to antibacterial usage in companion animal, veterinary and farm practices $\Lambda_{\rm A}$, the rate at which animals are colonised with resistant bacteria, γ , and the proportion of animals not already colonised (1 - A) (*Box 1A*).

220

 $\Lambda_{\rm E}$ represents the presence of antibacterial in the environment (derived from factories, pollution, wastewater etc), while (1 - E) represents the proportion of environmental samples negative for ABR bacteria. We assumed that the prevalence (percent of humans, animals or environmental samples that have resistant bacteria) of ABR bacteria declined at rates μ_H , μ_A and μ_E within humans, animals and the environment respectively.



228

Box 1: Two mechanisms of resistance driven by antibacterial exposure. First, antibacterial use selects resistant bacteria already present in the compartment, and second that antibacterial use can remove susceptible populations making transmission more likely (it is more likely for colonisation with resistant bacteria to occur when the native flora have been reduced/removed).

233

234 Second, we assumed that humans negative for ABR bacteria are exposed to and 235 acquire resistant bacteria from other humans at rate β_{HH} (representing transmission 236 in the open community and from patients, farm workers and other high-risk groups). 237 Acquisition in this context means the combined effects of stable colonisation with a 238 resistant bacterium following transfer, and infiltration of mobile resistance genes (e.g. 239 via plasmid) into the existing bacterial flora following transient colonisation with a transferred resistant bacterium. Similarly, animal-to-animal acquisition of resistance 240 occurs at rate β_{AA} , and animal-to-human transfer of resistance occurs at rate β_{AH} 241 (representing contact with farm animals, contact with companion animals and food 242 consumption). Human-to-animal transmission of resistance occurs at rate β_{HA} , 243 244 however this rate is smaller than the animal-to-human rate β_{AH} (as livestock to human jumps occur more frequently over evolutionary history than vice versa [10]). Similarly, 245 the rates of acquisition of resistance occur at β_{EH} for environment-to-human (drinking 246 water, non-animal food sources, swimming and bathing in freshwater), β_{EA} for 247 248 environment-to-animal (habitat, food sources, drinking water), β_{HE} for human-toenvironment (transfer through sewage) and β_{AE} for animal-to-environment (manure, 249 250 or composting of dead animals). We assumed that transmission from the environment 251 to animals was greater than that of the environment to humans ($\beta_{EA} > \beta_{EH}$), as a previous study showed that there were higher proportions of shared bacterial genera 252 253 in wastewater and animals, as opposed to wastewater and humans [27]. We also 254 assumed that the transmission within populations of humans and animals is greater

than the transmission between these populations and the transmission from the environment to these populations ($\beta_{HH} > \beta_{AH}, \beta_{EH}$ and $\beta_{AA} > \beta_{HA}, \beta_{EA}$).

257

We assumed that all rates of transmission are proportional to exposure with antibiotics, due to treatment eradicating susceptible bacteria in the host thereby enabling colonisation by incoming resistant bacteria (*Box 1B*, [11]). Therefore, the dynamics for the fraction of humans, animals and the environment with resistant bacteria is represented by the following ordinary differential equation model (Figure 1):

263

264
$$\frac{dH}{dt} = \gamma \Lambda_{\rm H} (1-H) + \Lambda_{\rm H} \beta_{\rm HH} H (1-H) + \Lambda_{\rm H} \beta_{\rm AH} A (1-H) + \Lambda_{\rm H} \beta_{\rm EH} E (1-H) - \mu_{\rm H} H$$

265
$$\frac{dA}{dt} = \gamma \Lambda_A (1-A) + \Lambda_A \beta_{AA} A (1-A) + \Lambda_A \beta_{HA} H (1-A) + \Lambda_A \beta_{EA} E (1-A) - \mu_A A$$

266
$$\frac{dE}{dt} = \Lambda_E \beta_{EE} E(1-E) + \Lambda_E \beta_{HE} H(1-E) + \Lambda_E \beta_{AE} A(1-E) - \mu_E E$$

267

For example, the rate of change over time for the fraction of humans with resistant bacteria $\frac{dH}{dt}$ = the rate at which susceptible humans become colonised with resistant bacteria $\gamma \Lambda_{\rm H}(1 - H)$ + the transmission from humans with ABR to susceptible humans $\Lambda_{H}\beta_{HH}H(1 - H)$ + the transmission from animals with ABR to susceptible humans $\Lambda_{H}\beta_{AH}A(1 - H)$ + the transmission of resistant bacteria in the environment to susceptible humans $\Lambda_{H}\beta_{EH}E(1 - H)$ – the loss of resistance $\mu_{H}H$ at each time point.

275

We assumed that $\Lambda_A > \Lambda_H$ as the majority of global ABU is within animals raised for food (73%, [5,6]). We further assumed that ABU is greater in humans when compared to the amounts present in the environment $\Lambda_H > \Lambda_E$, and that the rates of loss of resistance are equal in all three settings ($\mu_H = \mu_A = \mu_E$) in the absence of data on decay of resistance within different compartments.

The model was coded and numerically simulated using R v.1.2.5019. ODEs were solved using functions *deSolve* and *ode*.



Figure 1: Model schematic for human-animal-environment transmission of ABR in the One Healthsetting.

288

285

289 We identified estimates (Table 1) for the prevalence of gut colonisation with ESBL-290 producing E. coli in Thailand for healthy humans across an eight-year timeframe (2004 291 - 2012) [22-24.28.29], estimates of sample level positivity for resistant bacteria in rectal swabs from animals and fresh food from Thailand in 2012-2013 [24], and 292 293 environmental estimates of the proportion of bacteria that are resistant in Thailand 294 from canal water sources [24], stagnant water on food animal farms, and liquid from 295 hospital wastewater treatment tanks [30]. These data were used to calculate lower and upper bounds (95% credible intervals) in order to calibrate our model to a national-296 297 level Thailand-specific setting.

298

299 We assumed the widest possible range for parameters with no prior data and 300 extrapolated based on the hierarchy of transmission (e.g. human-human transmission 301 is greater or equal to animal-human transmission). Therefore, we allowed humanhuman transmission to take any possible value (from 0 - 100%), while animal-to-302 human transmission is a fraction of this value (0 - 100%) of human-human). We 303 304 explored the full range of transmission for animal-animal, animal-environment and 305 human-environment, while environment-human is a fraction of human-human, and human-animal and environment-animal are a fraction of the animal-animal rate (Table 306

307 1). This method ensures that we explored every possible scenario while maintaining

- 308 the structure of the model and the hierarchy of the separate transmission rates.
- 309
- 310 Similarly, we allowed ABU within animals to vary between the minimum and maximum
- 311 values (0 100%), while human use is a fraction of this (less than or equal to animal
- 312 use), and environmental use or contamination is a fraction of human use (Table 1).
- 313

314 **Results**

From 1 000 000 simulated parameter sets, 241 agreed well with the lower and upper bounds (Table 1) for the percentage of humans, animals and environmental samples colonised with resistant bacteria in Thailand (Figure 2). The fitting bounds for the percentage of humans with resistant bacteria was underestimated in 2009, perhaps due to discrepancy in sampling methodology or a different sampling cohort [29]. The full description of the prior and posterior parameter ranges can be found in the supplementary information (Figure S1).

322



323

Figure 2: Comparison of the model projections for animals, humans and the environment for the best 241 model fits (from 1 million samples). Error bars indicate data from which the model was calibrated 326 (3/4 for humans, aside from 2009) and shaded areas indicate the 95% confidence interval among all 327 fits. Model parameters and their uncertainty ranges can be found in Table 1.

328

329 The National Strategic Plan on AMR in Thailand

330 Table 2 shows the potential predicted impact of reduction in colonisation with resistant

331 bacteria in humans via interventions starting in 2020 and running for 20 years until

2040 (compared to the current standard of care). Over 20 years (2020-2040), the NSP-332 AMR in Thailand (which aims to reduce antimicrobial use in humans by 20%, animals 333 334 by 30% and increase public knowledge of AMR equating to an increase in all sanitary practices e.g. handwashing, safe drinking water, sewage disposal, waste water 335 336 treatment plants by 20%) was estimated to reduce the number of humans colonised 337 with resistant bacteria by 12.7% (95% credible interval: 7.0 – 21.0%, Table 2) from 2020 values by 2040. The NSP-AMR supplemented with an additional reduction in 338 human-based ABU (to 30%) would reduce the burden of resistance (% colonised with 339 340 resistant bacteria) within humans to a greater extent: to 17.1% (9.9 - 27.1%, Table 2) 341 of 2020 values. The NSP-AMR supplemented by an additional increase in sanitary 342 practices (to 30%, we predict an impact similar to reducing ABU by 30%: a reduction 343 of 16% (8.6 – 27.4%, Table 2) from 2020 values.

344

345 Without any ABU reduction, reducing all transmission rates in our model to 50% of 346 their original value was predicted to reduce the number of humans carrying resistant 347 bacteria to 15% (6.9 – 29.8%, Table 2) by 2040. However, the impact of reducing only 348 the transmission rates relating to water and the environment (human and animal 349 transmission to and from the environment) on colonisation in humans was relatively 350 low (1.3% reduction, 0.0 – 3.6%, Table 2). A 20% reduction in human ABU together with a 50% reduction in human-human transmission were projected to reduce the 351 human burden of resistance by 14.2% (7.7 – 22.7%, Table 2), while a 20% reduction 352 in human ABU with a 95% reduction in sewage or manure transmission was projected 353 to reduce the burden of human resistance by 7.8% over 20 years (4.8 – 12.4%, Table 354 355 2).

- 356
- 357

- 358 **Table 2:** Reduction in colonisation with resistant bacteria in humans between 2020 2040 for different
- 359 potential interventions. The National Strategic Plan on Antimicrobial Resistance (NSP-AMR; 2017-
- 360 2021) in Thailand aims to reduce antibiotic use (ABU) in humans by 20%, animals by 30% and increase
- 361 sanitary knowledge by 20% (in 2021). We investigate other hypothetical interventions aiming to reduce
- 362 ABU in humans and animals and other transmission related interventions.

Intervention or scenario	Median reduction in colonisation with resistant bacteria in humans (95% credible interval) 2020-2040		
NSP-AMR, Thailand	12.7 (7.0 – 21.0)		
NSP-AMR with 30% reduction in human ABU	17.1 (9.9 – 27.1)		
NSP-AMR with 30% increase in sanitary practices	16.0 (8.6 – 27.4)		
50% reduction in all transmission only	15.0 (6.9 – 29.8)		
50% reduction in water related transmission only	1.3 (0.0 – 3.6)		
20% reduction in human ABU with 50% reduction in human-human transmission	14.2 (7.7 – 22.7)		
20% reduction in human ABU with 95% reduction in transmission from sewage/manure	7.8 (4.8 – 12.4)		

363

Figure S2 shows the potential impact of simultaneously reducing ABU in humans and 364 365 animals (in intervals of 10%; 0, 10, 20, 30, 40 and 50%) and increasing sanitary practices (transmission remains at current levels, reducing transmission by 25%, 50% 366 367 and 75%). In the absence of any sanitary interventions aiming to reduce transmission, 368 achieving the NSP-AMR targets for ABU reduction would result in an impact of 7.3% 369 reductions in human colonisation of resistant bacteria by 2040. Increasing sanitary 370 practices to 25% would result in a 2.1-fold reduction in resistant bacteria colonisation 371 in humans (to 15.2%), while increasing sanitary practices by 50% and 75% would result in larger 3.5-fold (to 25.6%) and 7.2-fold (to 52.3%) reductions in the presence 372 373 of the current Thailand NSP-AMR targets.

374

375 Which factors contribute the most to human ABR?

The maximum potential reduction in colonisation with resistant bacteria for humans from single parameters in the model are summarised in Table 3 (more detail available in Table S1). While removing human ABU (0% ABU in humans) has the highest potential impact (72.3 – 99.8% reduction in colonisation of resistant bacteria over 20 years), reducing human-to-human transmission (7.4 – 38.8%), animal ABU (0.8 – 19.0%) and animal-to-human transmission (0.5 – 17.2%) all have considerable

382 potential impact. Environmental contamination and environment-to-human
383 transmission were both predicted to have a smaller impact (<6.2%).

384

	Median reduction in colonisation with
Parameter	resistant bacteria in humans (95%
i arameter	
	credible interval) 2020-2040
	,
Human ABU	72.3 – 99.8%
Human-to-human transmission	7 4 – 38 8%
Animal ABL	0.8 - 19.0%
, uniter / EO	0.0 10.070
Animal-to-human transmission	0 5 - 17 2%
	0.0 11.270
Environment contamination of AB	01-62%
	0.1 0.2 /0
Environment-to-human transmission	01-61%
	0.1 0.170

Table 3: The maximum reduction in resistant bacteria within human populations when accounting for

386 the effects of usage and transmission parameters. The maximum reduction can be achieved by totally

387 stopping human antibacterial use and human-human transmission, but animal and environmental

388 factors can still contribute significantly to reducing the burden of ABR within humans.

389

390 Table S1 shows the maximum potential reduction in colonisation with resistant 391 bacteria in humans for 30 scenarios, ranked by their relative contributions to human 392 ABR. The top four ranked scenarios were all related to human ABU (96% reduction in 393 colonisation over 20 years in humans). The next highest factors were the rate of loss 394 of resistant bacteria in humans (64.9%), followed by no transmission events (43.7%), 395 simultaneous human-human/human-environment/human-animal transmission 396 (19.5%) and human-human transmission alone (17.3%).

397

398 The relative attributable impact on the burden of colonisation of resistant bacteria 399 within human populations of human ABU compared to use in animals was determined to be 16:1 (16 times more impact could be achieved through reducing ABU in humans 400 rather than animals, Table S1). This ratio decreased to 13:1 when accounting for all 401 402 animal-based transmission. Likewise, the relative impact on human ABR of 403 environmental contamination of antibacterials was a ratio of 55:1 (50:1 when 404 accounting for environmental transmission events) but decreased to 10:1 when 405 combined with animal ABU and all environmental and animal-based transmission. 406 When comparing the relative impact of the human AMR burden to human-human

407 transmission, the ratio was 6:1 (six times more impact of reducing human ABU
408 compared to reducing human-human transmission), and comparing to all transmission
409 routes in the model resulted in a ratio of 2:1 (two times more impact of reducing human
410 ABU compared to reducing all transmission).

411

412 Which factors contribute the most to animal and environmental ABR?

413 The top ranked scenarios for both animals and the environment were all related to 414 ABU in animals and antibacterial contamination of the environment, respectively 415 (Table S1). Interestingly, removing all human usage (human ABU = 0) would result in 416 a 3.8% reduction in animals colonised with resistant bacteria, but a much greater 417 34.6% of the resistant contamination of bacteria in the environment. Removing animal 418 ABU (animal ABU = 0) resulted in a 96.4% reduction in animals and 30.8% reduction 419 in the environment, while removing environmental antibacterial contamination resulted 420 in 1.4% and 96.8% reductions in colonisation in animals and the environment, 421 respectively (Table S1).

422

423 **Discussion**

424 Prior to this study, an AMR literature review found that only 2% of published models 425 (five from a total of 273) considered human and animal transmission concurrently, and 426 no published model considered a third environmental setting [19]. To our knowledge, therefore, our study is the first to consider the One Health human-animal-environment 427 428 axes of ABR. This is an especially important factor to consider as human ABU, animal 429 ABU and environmental antibiotic contamination have all been shown to increase the 430 prevalence of ABR [6,10,31,32]. We propose this simple model as a first step in 431 understanding the complex picture [7] of One Health ABR, but our model framework 432 includes assumptions which should be recognised, and thus these results should be 433 interpreted in light of these assumptions.

434

First, prevalence data we used in the fitting of our model came from the six separate studies available in the literature – each with varying methodologies and cohorts. We did, however, explore the reliability of each of these national Thai estimates from 2004 to 2013 with a 95% confidence interval calculated for each reported data point – ensuring that we accounted for differences between these studies. There is a paucity

440 of data on the transmission of bacteria between the different compartments in any One 441 Health system, and no information at all for the situation in Thailand. Instead we 442 assumed a hierarchy of transmission based on other published studies from other 443 countries. For example, we used a study of shared bacterial genera in Beijing, China [27] to inform the assumption that environment-to-animal transmission is greater or 444 equal to that of environment-to-human transmission. We also used a wide range of 445 446 potential estimates (with 95% confidence intervals) and explored every possibility of 447 all underlying parameters.

448

449 Our model primarily considers ABR bacteria transmitted via the faecal-oral route and 450 those carrying mobile resistance genes (i.e. ESBL-producing *E. coli*, which is a very 451 common sentinel for ABR in a One-Health context) [24]. Whilst bacteria transmitted via faecal oral route make up a high proportion of the World Health Organisation list 452 453 of priority ABR pathogens [33], other types of resistant bacteria (e.g. MRSA) do not have an environmental reservoir, and indeed require close physical contact in order to 454 455 transmit – so this model does not capture those resistance mechanisms of all resistant 456 bacteria. Instead we focus on those bacteria which simultaneously affect all aspects 457 of the One Health network [24]. In addition, the lack of fit-for-purpose data to inform 458 this model may have skewed our results to favour humans as the most important factor 459 (as this is where the data is most rich), and future data may clarify the complete role of animals and the environment in human ABR. Future models should extend our 460 461 framework to these aspects and especially consider the setting-specific features of the population and their behaviour. This would result in a better understanding of the One 462 463 Health drivers of ABR in human populations.

464

Widespread concern around the contribution of animal antibacterials to human 465 466 resistance is growing, perhaps due to the majority of use, globally, occurring within 467 this sector [5,6], but the benefits of curtailing their use on human health remain 468 unquantified [10]. Here, the potential absolute impact of limiting the use of antibacterials in animals was predicted to be far less than then limiting human medical 469 470 use (16 times more impact achieved through reducing ABU in humans when 471 compared to animals) but this ratio was decreased when transmission between 472 animals and humans was accounted for (13 times more impact), and further 473 decreased when accounting for environmental contamination (10 times more impact). 474 This result suggests that while animal ABU has been highlighted as a major driver within human ABR [5], it is far more effective to reduce human ABU in the first instance. 475 476 However, reducing human ABU may not be feasible in many cases - and indeed 477 removing animal use entirely would also contribute to minimising the development of 478 ABR within animals (72 - 100%, Table S1) with substantial knock-on implications for 479 human health (up to an impact of 20% reductions by 2040). This suggests that animal 480 antibacterials are still an important driver for human resistance (albeit not as important 481 as human use). Removing animal use entirely is also not realistic if animals are being 482 used to produce food, and these results should be considered carefully for welfare 483 reasons, even when making minor reductions in use (this model does not suggest we 484 should reduce anything by 100%, rather that these results indicate which areas of the 485 One Health system yield maximum impact).

486

Limiting human ABU was six times as effective as reducing human-human transmission and twice as effective as reducing all transmission events. This suggests that interventions targeting reductions in ABR within human populations should also focus on improved hygiene and infection control (particularly for humans) in addition to curtailing ABU.

492

493 Overall, therefore, we predict that the most effective method of reducing the burden of 494 resistant bacteria in humans is to combine reductions in ABU while simultaneously 495 reducing transmission events between humans, animals and the environment, 496 reinforcing the need for One Health approaches that consider all three. This finding 497 agrees with the results of other studies: one such study found that animal ABU alone 498 had little impact on levels of human ABR [26] while another found that resistance in 499 hospitals could be better prevented by interventions simultaneously targeting 500 transmission and antibacterial exposure [32] - however none of these studies 501 considered ABU within a human-animal-environment One Health framework.

502

503 The current NSP-AMR in Thailand (2017-2021) aims to reduce ABU and transmission 504 simultaneously, which according to our results is the most efficient way of reducing 505 the burden of ABR in humans. We show that successfully achieving and maintaining 506 current targets [25] until 2040 would result in a reduction of 7.0 - 21.0% in the number 507 of people carrying resistant bacteria (assuming a 20% increase in sanitary practices

508 to decrease transmission through ABR public knowledge). This impact is reasonable 509 but could be improved by further reductions of human ABU (from 20% to 30%) (NSP-510 AMR; 9.9 – 27.1%). Alternatively, halving all transmission events alone (which depend on sanitary practices) without NSP-AMR targets being met was almost as effective in 511 512 reducing ABR (6.9 - 29.8%). This shows that there are multiple alternatives which 513 could strengthen the current NSP-AMR in Thailand. One such alternative is a 514 combined approach: the current NSP-AMR with 50% reductions in transmission 515 (compared to no change in sanitary practices) would be 3.5-times as effective in 516 reducing human colonisation with resistant bacteria (median 25.6% reduction over 20 517 years). This shows that the general impact of restricting ABU can be greatly enhanced 518 in the context of reduced transmission across various settings.

519

520 While our model is initially developed for the context of Thailand (the case study for 521 model parameterisation), these results are potentially generalisable to any country or 522 region with a high prevalence of resistant bacteria, including other Southeast Asian 523 countries (22% prevalence of faecal colonisation with ESBL producing 524 Enterobacteriaceae), African countries (22%), West Pacific countries (46%) or eastern 525 Mediterranean countries (15%) [18]. However, it would be unreasonable to assume 526 that each of these geographical regions share the exact parameters used in our Thailand study. For example, almost half of the Thai population are employed in the 527 agricultural sector [34] and 30.1% of people use water from natural sources [35]; while 528 some countries have similar demography, it will be important to collect parameter 529 530 estimates specific for each country and region. However, ABR research in LMICs is characterised by data gaps as well as variability in data reliability, sharing and capacity 531 532 [36]. In the absence of such data [36], this initial model may be used as a first step in 533 understanding and evaluating other LMICs' ABR strategies. Ideally, future studies 534 would obtain country-specific data on ABR (particularly for LMICs) or regional data 535 from these countries. Then, a similar data-driven approach could be used to predict 536 and forecast future ABR interventions with higher degrees of certainty in each specific 537 region.

538

539 Our model makes some important predictions which have direct implications for 540 human health in the context of ABR. Our conceptual model identified that human 541 antibacterials are the primary driver in human ABR, but that there are many such

interacting drivers which, if targeted by the correct interventions, could have large 542 implications for the wider ABR problem. Interventions which focus on reducing ABU in 543 544 humans can yield much greater impact when run in parallel to improved hygiene and 545 sanitation interventions. Future work is needed to develop this model framework and 546 to capture high-resolution data on transmission events between humans, animals and the environment, and to quantify the effects of ABU within animals and the 547 548 environment on human health. This model has allowed estimation of the impact of the 549 Thai NSP-AMR and has suggested where greater ambition in its targets could 550 significantly increase its potential impact on ABR. We anticipate that the results of this 551 modelling study will stimulate further discussion on One Health interventions within 552 Thailand and across other LMICs.

553

554 Acknowledgements

555 This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial 556 Resistance Cross Council Initiative supported by the seven United Kingdom research 557 councils and the National Institute for Health Research.

References

559	1.	O'Neill J. Tackling drug-resistant infections globally: Final report and
560		recommendations. The review on antimicrobial resistance. London: HM Government
561		and the Wellcome Trust; 2016.
562	2.	WHO. Antimicrobial resistance. Global report on surveillance. World Heal Organ.
563		2014. doi:10.1007/s13312-014-0374-3
564	3.	WHO. Global action plan on antimicrobial resistance. World Heal Organ. 2015.
565	4.	Hernando-Amado S, Coque TM, Baquero F, Martínez JL. Defining and combating
566		antibiotic resistance from One Health and Global Health perspectives. Nat Microbiol.
567		2019;4: 1432–1442. doi:10.1038/s41564-019-0503-9
568	5.	Van Boeckel TP, Glennon EE, Chen D, Gilbert M, Robinson TP, Grenfell BT, et al.
569		Reducing antimicrobial use in food animals. Science (80-). 2017;357: 1350–1352.
570		doi:10.1126/science.aao1495
571	6.	Van Boeckel TP, Pires J, Silvester R, Zhao C, Song J, Criscuolo NG, et al. Global
572		trends in antimicrobial resistance in animals in low- And middle-income countries.
573		Science (80-). 2019;365: eaaw1944. doi:10.1126/science.aaw1944
574	7.	Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al.
575		Understanding the mechanisms and drivers of antimicrobial resistance. Lancet.
576		2016;9: 176–187. doi:10.1016/S0140-6736(15)00473-0
577	8.	Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, et al.
578		Access to effective antimicrobials: a worldwide challenge. Lancet. 2015;387: 168-
579		175. doi:10.1016/S0140-6736(15)00474-2
580	9.	World Health Organization. The evolving threat of antimicrobial resistance: options for
581		action. Geneva. 2012.
582	10.	Woolhouse M, Ward M, Van Bunnik B, Farrar J. Antimicrobial resistance in humans,
583		livestock and the wider environment. Philos Trans R Soc B Biol Sci. 2015;370: 1–7.
584		doi:10.1098/rstb.2014.0083
585	11.	Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: A population
586		perspective. Emerg Infect Dis. 2002;8: 347–354. doi:10.3201/eid0804.010312
587	12.	Wernli D, Jørgensen PS, Morel CM, Carroll S, Harbarth S, Levrat N, et al. Mapping
588		global policy discourse on antimicrobial resistance. BMJ Glob Heal. 2017;2: e000378.
589		doi:10.1136/bmjgh-2017-000378
590	13.	Smith E, Lichten CA, Taylor J, MacLure C, Lepetit L, Harte E, et al. Evaluation of the

591		Action Plan against the rising threats from antimicrobial resistance. Final report.
592		European Commission. 2016.
593	14.	White A, Hughes JM. Critical Importance of a One Health Approach to Antimicrobial
594		Resistance. Ecohealth. 2019;16: 404–409. doi:10.1007/s10393-019-01415-5
595	15.	Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al.
596		Antimicrobial resistance: A global view from the 2013 World Healthcare-Associated
597		Infections Forum. Antimicrob Resist Infect Control. 2013;2. doi:10.1186/2047-2994-2-
598		31
599	16.	Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-
600		adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a
601		systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:
602		2197–2223. doi:10.1016/S0140-6736(12)61689-4
603	17.	Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, et al.
604		Burden of endemic health-care-associated infection in developing countries:
605		Systematic review and meta-analysis. Lancet. 2011;377: 228–241.
606		doi:10.1016/S0140-6736(10)61458-4
607	18.	Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal Colonization
608		with Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk
609		Factors among Healthy Individuals: A Systematic Review and Metaanalysis. Clin
610		Infect Dis. 2016;63: 310–318. doi:10.1093/cid/ciw283
611	19.	Niewiadomska AM, Jayabalasingham B, Seidman JC, Willem L, Grenfell B, Spiro D,
612		et al. Population-level mathematical modeling of antimicrobial resistance: A
613		systematic review. BMC Med. 2019;17: 1–20. doi:10.1186/s12916-019-1314-9
614	20.	Sumpradit N, Wongkongkathep S, Poonpolsup S, Janejai N, Paveenkittiporn W,
615		Boonyarit P, et al. New chapter in tackling antimicrobial resistance in Thailand. BMJ.
616		2017;358. doi:10.1136/bmj.j2423
617	21.	Phumart P, Phodha T, Thamlikitkul V, Riewpaiboon A, Prakongsai P, Limwattanon S.
618		Health and economic impacts of antimicrobial resistance in Thailand. J Health Serv
619		Res Policy. 2012;6: 352–360.
620	22.	Pongpech P, Naenna P, Taipobsakul Y, Tribuddharat C, Srifuengfung S. Prevalence
621		of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in
622		Escherichia coli from thai patients and healthy adults. Southeast Asian J Trop Med
623		Public Health. 2008;39: 425–433.
624	23.	Luvsansharav UO, Hirai I, Nakata A, Imura K, Yamauchi K, Niki M, et al. Prevalence
625		of and risk factors associated with faecal carriage of CTX-M β -lactamase-producing
626		enterobacteriaceae in rural Thai communities. J Antimicrob Chemother. 2012;67:
627		1769–1774. doi:10.1093/jac/dks118

628 Boonyasiri A, Tangkoskul T, Seenama C, Saiyarin J, Tiengrim S, Thamlikitkul V. 24. 629 Prevalence of antibiotic resistant bacteria in healthy adults, foods, food animals, and 630 the environment in selected areas in Thailand. Pathog Glob Health. 2014;108: 235-631 245. doi:10.1179/2047773214Y.0000000148 632 Ministry of Public Health, Ministry of Agriculture and Cooperatives. National Strategic 25. 633 Plan on Antimicrobial Resistance 2017-2021, Thailand. 2016. 634 doi:10.2471/BLT.16.179648 van Bunnik BAD, Woolhouse MEJ. Modelling the impact of curtailing antibiotic usage 635 26. 636 in food animals on antibiotic resistance in humans. R Soc Open Sci. 2017;4: 161067. 637 doi:10.1098/rsos.161067 638 27. Pal C, Bengtsson-Palme J, Kristiansson E, Larsson DGJ. The structure and diversity 639 of human, animal and environmental resistomes. Microbiome. 2016;4. 640 doi:10.1186/s40168-016-0199-5 641 28. Sasaki T, Hirai I, Niki M, Nakamura T, Komalamisra C, Maipanich W, et al. High 642 prevalence of CTX-M β-lactamase-producing enterobacteriaceae in stool specimens 643 obtained from healthy individuals in Thailand. J Antimicrob Chemother. 2010;65: 666-644 668. doi:10.1093/jac/dkq008 645 29. Luvsansharav UO, Hirai I, Niki M, Sasaki T, Makimoto K, Komalamisra C, et al. 646 Analysis of risk factors for a high prevalence of extended-spectrum β-lactamase-647 producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. J Med 648 Microbiol. 2011;60: 619-624. doi:10.1099/jmm.0.026955-0 649 30. Thamlikitkul V, Tiengrim S, Thamthaweechok N, Buranapakdee P, Chiemchaisri W. 650 Contamination by Antibiotic-Resistant Bacteria in Selected Environments in Thailand. 651 Int J Environ Res Public Health. 2019;16: 1–11. 652 31. Kristiansson E, Fick J, Janzon A, Grabic R, Rutgersson C, Weijdegård B, et al. 653 Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of 654 resistance and gene transfer elements. PLoS One. 2011;6: e17038. 655 doi:10.1371/journal.pone.0017038 Knight GM, Costelloe C, Deeny SR, Moore LSP, Hopkins S, Johnson AP, et al. 656 32. 657 Quantifying where human acquisition of antibiotic resistance occurs: A mathematical 658 modelling study. BMC Med. 2018;16: 1–11. doi:10.1186/s12916-018-1121-8 659 33. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of 660 661 antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18: 318-327. 662 doi:10.1016/S1473-3099(17)30753-3 663 34. Coyne L, Arief R, Benigno C, Giang VN, Huong LQ, Jeamsripong S, et al. 664 Characterizing antimicrobial use in the livestock sector in three south east asian

665	countries (Indonesia,	Thailand, and Vie	tnam). Antibiotics. 2019;8: 33.
-----	-----------------------	-------------------	---------------------------------

- 666 doi:10.3390/antibiotics8010033
- 667 35. Khamsarn S, Nampoonsak Y, Busamaro S, Tangkoskul T, Seenama C,
- 668 Rattanaumpawan P, et al. Epidemiology of antibiotic use and antimicrobial resistance
- in selected communities in Thailand. J Med Assoc Thail. 2016;99: 1–6.
- 670 36. Ashley EA, Shetty N, Patel J, Van Doorn R, Limmathurotsakul D, Feasey NA, et al.
- 671 Harnessing alternative sources of antimicrobial resistance data to support surveillance
- 672 in low-resource settings. J Antimicrob Chemother. 2019;74: 541–546.
- 673 doi:10.1093/jac/dky487

676 **Table 1:** Parameters and fitting metrics used in the model (summary of 95%)

677 confidence interval uncertainty ranges). HH = human-human, AH = animal-human, AA

678 = animal-animal.

Model Parameters	Parameter value (95%	Source		
	confidence interval)	Course		
Antibacterial usage				
Animala	0 100%	Majority of antimicrobials used in animals raised for		
Animais	0 - 100%	food (73%, [5,6])		
Human	0 – 100% of animal use			
Environment	0 – 100% of human use			
Transmission of ABR				
Humans to humans	0.0 - 100.0 %	Explore full parameter space		
Animals to humans	0.0 – 100.0% of HH	Fraction of HH transmission		
Environment to humans	0.0 – 100.0% of HH	Fraction of HH transmission		
Animals to animals	0.0 - 100.0%	Explore full parameter space		
Humana ta animala	0.0 100% of AH and AA	Assume wide range, but less than AH [10] and AA		
	0.0 – 100 % OF ATT and AA	transmission		
Environment to animals	0.0 100.0% of AA	Fraction of animal animal transmission		
(habitat/ drinking water)	0.0 - 100.0 % OF AA			
Humans to environment	0.0 100.0%	Explore full parameter space		
(sewage)	0.0 - 100.070			
Animals to environment	0.0 - 100.0%	Explore full parameter space		
(manure)	0.0 - 100.070			
Carriage of resistance				
Rate of loss of resistant	0_100%	Explore full parameter space		
bacteria after 12 months	0-100 /6			
Fitting Parameters	Value (95% confidence	Source		
Thung Farameters	interval)			
Prevalence of colonisation with	ESBL-producing organisms			
Humans				
2004	0.0 - 0.0%	0/120 healthy adults in Thailand [22]		
2008	16.7 62.1%	87/160 healthy asymptomatic volunteers in		
2000	40.7 - 02.170	Thailand [28]		
2000	35.2 11.3%	177/445 healthy asymptomatic volunteers in		
2000	55.2 - 44.570	Thailand [29]		
2010	64 0 73 7%	289/417 door to door sampling among healthy		
2010	0 1 .0 - 10.1 /0	individuals in Thailand [23]		
2012	71 4 - 78 5%	430/574 healthy workers in a food factory and food		
	11. T 10.0/0	animal farm in Thailand [24]		

		Upper bound from rectal swabs in pigs (241/400),		
Animals	11.1 – 60.3%	lower bound from fresh food (12/54) in Bangkok		
		and East/North Thailand [24]		
Rectal swabs of animals, 2012-2	2013			
Pig	55.4 - 65.0%	241/400 in East/North Thailand [24]		
Broiler	26.9 - 48.1%	30/80 in East/North Thailand [24]		
Laying Hen	0.0 - 7.7%	2/61 in East/North Thailand [24]		
Fresh pork meat	0.0 – 25.6%	2/18 in East/North Thailand [24]		
Fresh food, 2012-2013				
Chicken	4.9 - 52.2%	4/14 in Bangkok & central [24]		
Pork	28.1 – 78.6%	8/15 in Bangkok & central [24]		
Beef	0.0 - 0.0%	0/11 in Bangkok & central [24]		
Fish	0.0 - 0.0%	0/14 in Bangkok & central [24]		
		Lower bound from water in Bangkok and central		
Environment	0.0 - 24.7%	province [24] and upper bound from stagnant water		
		on food animal farms [24]		
Canal water, 2012-2013	0.0 – 19.3%	1/15 in Bangkok and central [24]		
Stagnant water on food	0.0 - 24.7%	3/25 in Bangkok and central [2/]		
animal farms, 2012-2013	0.0 - 24.770			
Effluent fluid after				
treatment with chlorine prior	24-176%	6/60 in public hospitals in Thailand [30]		
to draining into a public water	2.7 17.070			
source from hospitals				

680 Supplementary Information



681

Figure S1: Parameter prior and posterior distributions. Grey boxes represent the search range/prior distribution of parameters (taken from Table 1), while red boxes represent the posteriors from the best 241 hundred fits (from a sample of 1 million), with interquartile range shaded, median, and minimum and maximum values.





688 689 Figure S2: The relationship between reducing transmission via increasing knowledge of 690 sanitary measures and antibacterial use in humans and animals. Black square indicates the 691 current National Strategic Plan on Antimicrobial Resistance (2017-2021) (NSP-AMR) targets 692 for 0, 25, 50, 75 and 100% reductions in sanitary related transmission. With 20% reductions 693 in use in humans, and 30% in animals, alongside no reduction in transmission related to 694 education or prevention would reduce ABR in humans by 7.3%. A 25% increase in sanitary 695 practices would result in 2.1-fold higher reductions in human ABR, 50% would result in 3.5-696 fold higher impact (25.6% reduction in human ABR) and 75% increases in sanitary practices 697 would result in 7.2-fold higher impact (52.3% reduction in human resistance).

		Median reduction in	Median reduction in	Median reduction in
		colonisation with resistant	colonisation with resistant	colonisation with resistant
Intervention	Parameters	bacteria in humans (95%	bacteria in animals (95%	bacteria in the environment
		credible interval) 2020-	credible interval) 2020-	(95% credible interval) 2020-
		2040	2040	2040
	$\Lambda_H = \Lambda_A$			
No antibacterial use and no transmission	$= \Lambda_E = 0$	96.4 (72.3 – 99.8%)	96.4 (72.3 – 99.8%)	96.8 (82.3 – 99.8%)
	$\beta = 0$			
No antibacterial use	$\Lambda_H = \Lambda_A$	96.4 (72.3 – 99.8%)	96.4 (72.3 – 99.8%)	96.8 (82.3 – 99.8%)
	$=\Lambda_E=0$. , ,
No human antibacterial use	$\Lambda_H = 0$	96.4 (72.3 – 99.8%)	3.8 (0.4 – 23.5%)	34.6 (3.2 – 82.0%)
No human antibacterial use and no human to	$\Lambda_H = 0$			
human, human to environment, human to	$\beta_{HH} = \beta_{HE}$	96.4 (72.3 – 99.8%)	4.5 (0.6 – 25.8%)	42.4 (4.2 – 91.1%)
animal transmission	$=\beta_{HA}=0$			
Increasing rate of loss of resistance in humans	<i>u</i> – 1	64 9 (45 8 - 78 0%)	2.7 (0.4 – 11.0%)	25.0 (2.7 – 56.0%)
to max	$\mu_H = 1$		2.7 (0.4 11.070)	20.0 (2.7 00.070)
No transmission	$\beta = 0$	43.7 (17.2 – 81.4%)	23.9 (3.2 – 74.4%)	96.8 (82.3 – 99.8%)
No human to human, human to environment,	$\beta_{HH} = \beta_{HE}$	105(92 41 70/)	4.5 (0.6 25.99/)	42.4 (4.2 01.19/)
human to animal transmission	$=\beta_{HA}=0$	19.5 (0.5 – 41.7 %)	4.5 (0.0 - 25.6 %)	42.4 (4.2 - 91.170)
No human to human transmission	$\beta_{HH} = 0$	17.3 (7.4 – 38.8%)	0.7 (0.1 – 4.3%)	6.0 (0.6 – 23.5%)
No antibacterial use in animals and	$\Lambda_A = \Lambda_E = 0$			
environment, no animal to animal, animal to	$\beta_{AA} = \beta_{AH}$			
human, animal to environment, no	$=\beta_{AE}=0$	9.2 (1.7 – 24.1%)	96.4 (72.3 – 99.8%)	96.8 (82.3 – 99.8%)
environment to animal, environment to human,	$\beta_{EA} = \beta_{EH}$			
environment to environment transmission	$=\beta_{EE}=0$			

No antibacterial use in animals and environment, no animal to animal, animal to environment, no environment to animal, environment to environment transmission	$\Lambda_A = \Lambda_E = 0$ $\beta_{AA} = \beta_{AE}$ = 0 $\beta_{EA} = \beta_{EE}$ = 0	8.3 (1.4 – 23.2%)	96.4 (72.3 – 99.8%)	96.8 (82.3 – 99.8%)
No animal antibacterial use and no animal to human, animal to environment, animal to animal transmission	$\Lambda_A = 0$ $\beta_{AH} = \beta_{AE}$ $= \beta_{AA} = 0$	7.2 (1.2 – 19.5%)	96.4 (72.3 – 99.8%)	37.2 (4.7 – 90.6%)
No animal to animal, animal to human, animal to environment transmission	$\beta_{AA} = \beta_{AH}$ $= \beta_{AE} = 0$	7.2 (1.2 – 19.5%)	13.9 (1.7 – 52.7%)	37.2 (4.7 – 90.6%)
No animal antibacterial use	$\Lambda_A = 0$	6.2 (0.8 – 19.0%)	96.4 (72.3 – 99.8%)	30.8 (4.1 – 81.6%)
No human to animal, animal to human transmission	$\beta_{HA} = \beta_{AH}$ $= 0$	5.7 (0.5 – 17.4%)	3.5 (0.3 – 21.8%)	3.3 (0.4 – 12.7%)
No animal to human transmission	$\beta_{AH} = 0$	5.6 (0.5 – 17.2%)	0.2 (0.0 – 2.1%)	1.7 (0.1 – 9.5%)
Increasing rate of loss of resistance in animals to max	$\mu_A = 1$	4.6 (0.8 – 10.0%)	71.3 (57.7 – 81.5%)	25.5 (3.1 – 59.0%)
No environment antibacterial use and no environment to human, environment to environment, environment to animal transmission	$\Lambda_E = 0$ $\beta_{EH} = \beta_{EE}$ $= \beta_{EA} = 0$	2.0 (0.1 – 6.3%)	1.5 (0.1 – 9.0%)	96.8 (82.3 – 99.8%)
No environment to animal, environment to human, environment to environment transmission	$\beta_{EA} = \beta_{EH}$ $= \beta_{EE} = 0$	2.0 (0.1 – 6.3%)	1.5 (0.1 – 9.0%)	12.6 (0.7 – 56.3%)

	No environment to human, environment to animal, animal to environment, human to	$eta_{EH} = eta_{EA}$ $= eta_{AE}$	2.0 (0.1 – 6.3%)	1.5 (0.1 – 9.0%)	93.5 (40.7 – 99.6%)
	environment transmission	$=\beta_{HE}=0$			
ĺ	No environment to human, human to	$\beta_{EH} = \beta_{HE}$	1.9 (0.1 – 6.1%)	0.5 (0.0 – 4.3%)	39.1 (2.3 – 91.1%)
	environment transmission	= 0			
	No environment to human transmission	$\beta_{EH} = 0$	1.8 (0.1 – 6.1%)	0.1 (0.0 – 0.6%)	0.5 (0.0 – 2.4%)
ĺ	No environment antibacterial use	$\Lambda_E = 0$	1.7 (0.1 – 6.2%)	1.4 (0.0 – 8.7%)	96.8 (82.3 – 99.8%)
	Increasing rate of loss of resistance in the	$\mu_{\rm F} = 1$	1.5 (0.1 – 4.9%)	1.2 (0.0 – 6.8%)	82.4 (68.3 – 92.4%)
	environment to max	T E			
ĺ	No animal to animal transmission	$\beta_{AA} = 0$	0.7 (0.0 – 5.4%)	12.4 (1.6 – 48.6%)	3.7 (0.2 – 25.1%)
	No human to environment transmission	$\beta_{HE} = 0$	0.6 (0.0 – 3.2%)	0.4 (0.0 – 4.2%)	39.1 (2.3 – 91.1%)
	No environment to animal, animal to	$\beta_{EA} = \beta_{AE}$	0.6(0.0 - 3.0%)	1.3 (0.0 – 9.0%)	34.2(2.3 - 90.0%)
	environment transmission	= 0			
ĺ	No animal to environment transmission	$\beta_{AE} = 0$	0.5 (0.0 – 3.0%)	0.3 (0.0 – 4.1%)	34.2 (2.3 – 90.0%)
	No environment to environment transmission	$\beta_{EE} = 0$	0.2 (0.0 – 1.9%)	0.1 (0.0 – 2.3%)	11.1 (0.4 – 55.8%)
ĺ	No human to animal transmission	$\beta_{HA} = 0$	0.2 (0.0 – 2.0%)	3.5 (0.2 – 21.6%)	1.1 (0.0 – 9.2%)
	No environment to animal transmission	$\beta_{EA} = 0$	0.1 (0.0 – 0.7%)	1.2 (0.0 – 9.0%)	0.3 (0.0 – 3.7%)

698 **Table S1:** Reduction in colonisation with resistant bacteria in humans, animals and the environment from 2020-2040, in order of impact on human burden of

699 resistant bacteria for combinations of use and transmission and loss of resistance.